Johnson & Johnson (NYSE:JNJ) has lost a court battle over its drug-coated stent patents after a New Jersey federal judge ruled that stents marketed by Boston Scientific (NYSE:BSX) Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) had not infringed stent patents held by the New Brunswick, New Jersey company.Despite the ruling, a Johnson & Johnson spokeswoman said [...]

Every week, MedCity News highlights the best of its MedCitizens: syndication partners and MedCity News readers who discuss life science current events on MedCityNews.com. Now here’s the best of what YOU had to say.

A look at how Boston Scientific has shaped the emerging med tech landscape, and where the ex-BSC-ers are making their impact now.

Johnson & Johnson’s (NYSE:JNJ) Michael Mahoney will begin leading Boston Scientific (NYSE:BSX) in October, first as president and then begin his tenure at CEO in November. Mahoney joins Boston Scientific at a challenging time, as the company struggles with limited growth in its heart device markets, which generate 70 percent of its total [...]

Paulson & Co. Inc. is Boston Scientific Corp.’s (NYSE:BSX) largest shareholder no more, after liquidating its position in BSX completely by selling off some 15 million shares of the Natick, Mass.-based medical device company during the second quarter.The New York-based fund has been steadily selling off its BSX shares for more than [...]

The cardiac rhythm management industry looks like it needs of a jolt of its own, badly.A look at the earnings releases of two of the big three players in the CRM Market, Boston Scientific (NYSE:BSX) and St. Jude Medical (NYSE:STJ), reveals that the slump in the cardiac rhythm management business is more persistent than some [...]

Shares of Boston Scientific Corp. (NYSE:BSX) traded at unusually high volumes for two straight weeks during the recent roller coast on Wall Street, coming in at more than 120 million trades during the week ending July 29 and topping 140 million the week ending August 5.Last week shaped up to top [...]

Boston Scientific Corp. (NYSE:BSX) plans to spend $37 million on overseas research and development, this time at its R&D facility in Clonmel, Ireland.The Natick, Mass.-based company hopes to jump-start development of a next generation cardiac rhythm management system.The funding is partially supported by a grant from IDA Ireland, a quasi-public investment promotion agency, which also [...]

With all the turmoil in the US healthcare market, a port in the storm is not easy to find. A port that can accommodate an outsized tanker ship like Medtronic is even harder to locate. With two back-to-back acquisitions last month of Peak Surgical and Salient Surgical, the S.S. Medtronic took refuge in Surgery Harbor, committing nearly $600 million (net of previous ownership stakes) in a single day to nestle in with the hulking barges of Covidien and J&J.

In the stockapocalypse that was Manic Monday, medical technology and pharma stocks got a mere slap on the wrist compared with banking stocks that received a more humiliating pants-down whipping.It appears that pharma stocks fared better than medical device and biotech stocks. GlaxoSmithKline (NYSE:GSK) was down a mere 28 cents to close at $39.44 on [...]